
CD276
20
MENTIONS
11
EPISODES
10
PODCASTS
Search complete. 20 mentions across 11 episodes found for "CD276".
Nov 19, 2026
S19 Ep22: SCLC Treatment Advances Compound With EGFR- and KRAS-Directed NSCLC Updates at ESMO 2026
C
8:19Chandler ParkHOST
You have a lot of referrals for small cell.
T
8:22Tejas PatilGUEST
Yeah, I mean, I think the things to watch for in this space are going to be where do B7H3 antibody drug conjugates fit in, where do DLL3 antibody drug conjugates fit in.
T
8:31Tejas PatilGUEST
You know, one thing that'll be interesting to watch in the coming years is will we finally get to an era where platinum etoposide is no longer necessary because an ADC plus tarlatumab might actually, or some DLL3 T-cell engager might supplant platinum etoposide.
T
8:48Tejas PatilGUEST
So I think that's going to be in the horizon, and I'm looking forward to that data.
C
12:07Chandler ParkHOST
And then, you know, I'll stay on that line.
C
12:08Chandler ParkHOST
I mean, I think another big study that occurred here, I guess, and world long is, you know, this extension of the antibody drug conjugate.
C
12:16Chandler ParkHOST
And we had the B7H3, the Taishan 302, which study evaluated tambolutamide pelletecan, a B7H3 directed antibody drug conjugate against topotecan.
C
12:29Chandler ParkHOST
Median overall survival was 13.3 versus 9.4. What do you think about, we talked about the ADCs, Tejas, and how it, you know, knock on wood, hopefully kind of replace the platinum etoposide.
ProFound Uses AI to Map the Dark Genome
S
25:33Sam FazeliHOST
I've just come back from ESMO, which is the second biggest oncology conference globally.
S
25:39Sam FazeliHOST
ADCs are everywhere, B7H3, CES6, TROP2.
S
25:44Sam FazeliHOST
I mean, you name it.
S
25:46Sam FazeliHOST
But they all have, of course, part of the issue is not the antibody or the antigen.
Episode 127: In the Clinic - Beyond targeted therapy in lung cancer with Dr Tom Newsom-Davis
T
9:12Tom Newsom-DavisGUEST
There were two trials that came out of China presented at the World Lung Conference in Korea about four weeks ago.
T
9:18Tom Newsom-DavisGUEST
And they're ADCs against B7H3.
T
9:21Tom Newsom-DavisGUEST
B7H3 is expressed on neuroendocrine cells and is expressed on about 70 or 80 percent of them.
T
9:27Tom Newsom-DavisGUEST
So it's quite a common marker.
T
9:29Tom Newsom-DavisGUEST
And they either gave an ADC, there's two of them, one's called Tampelli and one's called Rizrez.
T
10:19Tom Newsom-DavisGUEST
So that makes me think that they are going to be agents that we will commonly use in the second line treatment of small cell.
T
10:27Tom Newsom-DavisGUEST
And so that's very interesting.
T
10:29Tom Newsom-DavisGUEST
There are also other antibody drug conjugates which are no longer going to be targeting one target like B7H3.
Episode 530: ESMO 2026 Review
S
17:38Silke GillisonGUEST
But
T
17:39Tom PowlesHOST
there was some nice B7H3 work as well, I think.
T
17:40Tom PowlesHOST
So there was a
B
17:40Brian RiniHOST
study with B7H3
T
17:41Tom PowlesHOST
topo-1-ADC plus a PD-L1 VEGF-Bi specific from BioNTech.
T
17:59Tom PowlesHOST
And that, but it wasn't in prostate cancer, but it was across broad groups of different tumor groups and had a lot of activity.
T
18:09Tom PowlesHOST
And there was also another ADC, PSMA, STEEP1, dual target, TOPO1 payload, abv969 in a phase one that shows some really deep responses too so i kind of looked around and felt there were just lots of new exciting things you could do in prostate cancer which weren't targeting the traditional kind of rp taxane access that we've been doing so i thought it was a really cool meeting for that you know
S
18:38Silke GillisonGUEST
Yeah, but you know, even last year we have seen the CaliCrane 2, the bispecific T-cell engager, the STIOP is quite far away.
Scrip's Five Must-Know Things: US COINS Impact, GSK's Oncology Turnaround, Lilly's KRAS Push
I
5:15Ian HaydockHOST
Meals insisted that the Azure One data was stunning.
I
5:19Ian HaydockHOST
He also referenced GSK's Hanso Pharma-partnered antibody drug conjugate Rizvitatog-Rezetacan and the Phase 3 Artemis 011 study, investigating the B7H3 targeted drug for osteosarcoma.
I
5:33Ian HaydockHOST
Just before ESMO, GSK reported positive results from its global Phase 1B trial of the ADC in extensive-stage small-cell lung cancer.
I
5:43Ian HaydockHOST
There was also a positive presentation in the Spanish capital of data on the other ADC that GSK licensed from Hanso, the B7H4 targeted candidate Mosatatug Resetecan.
S19 Ep17: Perioperative Research Success Is Set to Transform Bladder Cancer Care After ESMO 2026
P
37:16Petros GrivasGUEST
And I think the question is, How do we go from here based on this data set, I think is an important one.
P
37:23Petros GrivasGUEST
There are other ADCs under development, phase two, phase three trials, targeting TROP2, HER2, B7H3 and other targets.
P
37:33Petros GrivasGUEST
And I think that the future is bright.
P
37:37Petros GrivasGUEST
and based on the ongoing investigation and builds upon a very exciting present.
Hot Topics: Current Barriers to Myeloid Therapy
A
32:56Amy HeimbergerGUEST
But I do think we've got a new constellation of targets that have been emerging.
A
33:00Amy HeimbergerGUEST
You know, I think B7H3 is quite an interesting target.
A
33:03Amy HeimbergerGUEST
I think there's some new CAR targets that are going after immune markers that I think are quite interesting.
A
33:10Amy HeimbergerGUEST
But again, we have to do the hard work.
Highlights from ESMO 2026
V
17:50Valentina BoniSOUNDBITE_SPEAKER
One is the bispecific antibody.
V
17:53Valentina BoniSOUNDBITE_SPEAKER
We have seen the new emerging modalities of bispecific ADC, in particular dual targeting of EGFR with CMAT and B7H3.
V
18:07Valentina BoniSOUNDBITE_SPEAKER
But we have seen also the potential role of a new combination of anti-PD1 VGF combining with ADC.
V
18:18Valentina BoniSOUNDBITE_SPEAKER
It was presented phase 2 combining LFD with Pumitamide.
Prostate Cancer — An Interview with Prof Karim Fizazi
K
30:54Karim FizaziGUEST
I think they are coming.
K
30:56Karim FizaziGUEST
For example, those that are targeting B7H3 are very promising.
K
31:01Karim FizaziGUEST
There are many of them being tested or about to be tested in phase 3.
K
31:08Karim FizaziGUEST
There are also PSMA-targeted ADCs.
Prostate Cancer — An Interview with Prof Karim Fizazi
K
30:54Karim FizaziGUEST
I think they are coming.
K
30:56Karim FizaziGUEST
For example, those that are targeting B7H3 are very promising.
K
31:02Karim FizaziGUEST
There are many of them being tested or about to be tested in phase 3.
K
31:08Karim FizaziGUEST
There are also PSMA-targeted ADCs.
1 more episode mentions CD276.
Create an account to see the whole feed, search across every transcript, and follow the entities you care about.